Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
Rebecca S Hunter, Ann-Marie Lobo Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA Abstract: Uveitis can be a sight-threatening eye disease with significant morbidity. Corticosteroids remain the mainstay of treatment of uveitis and provide an e...
Guardado en:
Autores principales: | Hunter RS, Lobo AM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f3cb4482fa3740d89096cf1e0f77ec81 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
por: Jane S Myung, et al.
Publicado: (2010) -
Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion
por: Ryder SJ, et al.
Publicado: (2015) -
Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard Jr JD, et al.
Publicado: (2012) -
Noninfectious uveitis: strategies to optimize treatment compliance and adherence
por: Dolz-Marco R, et al.
Publicado: (2015) -
Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis
por: Tufail A, et al.
Publicado: (2018)